BackPharmaron Beijing , Ltd. Overview

Pharmaron Beijing , Ltd. Receivables

Pharmaron Beijing , Ltd.'s receivables is $3.7B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$3.68B
↑ 20.05% YoYΔ $615.41M vs prior year quarter

Peer trimmed avg / median

Loading

Pharmaron Beijing , Ltd. Receivables History

Loading

Pharmaron Beijing , Ltd. vs. peers: Receivables Comparison

Loading

Pharmaron Beijing , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pharmaron Beijing , Ltd. (3759.HK) FAQ

The latest receivables for 3759.HK is $3.7B as of September 2026. That compares with $3.1B in the prior-year period — up 20.1% year over year. Investors often review this figure alongside Pharmaron Beijing , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 3759.HK's receivables moved from $3.1B to $3.7B — a 20.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pharmaron Beijing , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $3.7B for 3759.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 3759.HK's receivables ($3.7B), review year-over-year change from $3.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Pharmaron Beijing , Ltd.'s receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.